Mark Foletta
Interim Independent Board Chair
Chair of the Audit Committee
Board member since 2014
With more than two decades of financial leadership in healthcare, Mr. Foletta brings deep expertise in audit oversight, capital allocation, and financial strategy that supports Dexcom’s continued growth and operational discipline.
Career Highlights:
- Former Executive Vice President and Chief Financial Officer of Tocagen, Inc. from February 2017 to June 2020
- Former Senior Vice President and Chief Financial Officer of Amylin Pharmaceuticals until its acquisition by Bristol Myers Squibb, from March 2000 to August 2012, overseeing capital structure and investor communications
Other Directorships – Current:
- AMN Healthcare Services (Board Chair); Enanta Pharmaceuticals (Chair of Audit Committee)
Key Experience and Qualifications:
- Audit and financial leadership experience at public healthcare companies
- Public company board experience
Other Professional Experience and Community Involvement:
- Member of the Corporate Directors Forum
Education:
- B.A. in Business Economics from UC Santa Barbara